ARDX (Ardelyx) Cash-to-Debt : 1.63 (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Ardelyx Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ardelyx's cash to debt ratio for the quarter that ended in Dec. 2024 was 1.63.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Ardelyx could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Ardelyx's Cash-to-Debt or its related term are showing as below:

ARDX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.63 Med: 3.46 Max: No Debt
Current: 1.63

During the past 13 years, Ardelyx's highest Cash to Debt Ratio was No Debt. The lowest was 1.63. And the median was 3.46.

ARDX's Cash-to-Debt is ranked worse than
70.04% of 1482 companies
in the Biotechnology industry
Industry Median: 7.44 vs ARDX: 1.63

Ardelyx Cash-to-Debt Historical Data

The historical data trend for Ardelyx's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Ardelyx Cash-to-Debt Chart

Ardelyx Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

3.50

2.56

3.40

3.29

1.63

Ardelyx Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															3.29	1.93	1.77	1.82	1.63

Competitive Comparison of Ardelyx's Cash-to-Debt

For the Biotechnology subindustry, Ardelyx's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ardelyx's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ardelyx's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Ardelyx's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Ardelyx Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Ardelyx's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	250.1	/	(1.562	+	151.876)
	=	1.63

Ardelyx's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	250.1	/	(1.562	+	151.876)
	=	1.63

Ardelyx (NAS:ARDX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Ardelyx Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Ardelyx's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ardelyx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (NAS:ARDX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

41X:Germany

Address

400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451

Website

https://www.ardelyx.com

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Executives

Michael Raab	director, officer: President & CEO	1119 ST PAUL STREET, BALTIMORE MD 21202
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
Laura A Williams	officer: Chief Medical Officer	116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Justin A Renz	officer: Chief Financial Officer	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Elizabeth A Grammer	officer: See Remarks	78TH FOURTH AVENUE, WALTHAM MA 02451
Robert Blanks	officer: See Remarks	C/O ARDELYX, 34175 ARDENWOOD BLVD., FREMONT CA 94555
David P. Rosenbaum	officer: Chief Development Officer	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Robert Ora Felsch	officer: See Remarks	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD., FREMONT CA 94555
Susan Rodriguez	officer: Chief Commercial Officer	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Forest Baskett	10 percent owner
Scott D Sandell	10 percent owner
Jeffrey W Jacobs	officer: VP, Chemistry	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Keith Santorelli	officer: See Remarks	C/O ARDELYX, INC. 34175 ARDENWOOD BLVD, FREMONT CA 94555
Onaiza Cadoret-manier	director	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010